{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:26:52Z","timestamp":1759177612930,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100030902","name":"Martin-Luther-Universit\u00e4t Halle-Wittenberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030902","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Erenumab is a monoclonal antibody specifically targeting the CGRP-receptor. Several studies showed efficacy and safety in patients with migraine. Less is known regarding dosage increase, especially in a difficult to treat patients. The aim of the study is to evaluate the increased dosage under real world conditions with particular focus on 70\u00a0mg non-responders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In a retrospective analysis, patients treated in tertiary headache centers (Halle or Jena, Germany) receiving 70\u00a0mg erenumab for at least 3 months with a dosage increase to 140\u00a0mg were analyzed. Data were evaluated regarding headache days, intake of acute medication, previous prophylaxis, and medication overuse. Baseline and all treatment intervals were determined as three-month periods.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Datasets of 52 migraine patients (90.4% women) aged between 22 and 78 years (mean 50.4 years, SD 12.1 years) were analyzed. At baseline (mean headache-days 15.67\u2009\u00b1\u20096.37) 51.9% met criteria for chronic migraine and 56% were currently overusing acute medication. While therapy with 70\u00a0mg showed significant improvement in headache days and 50% response, further improvement was not achieved for therapy escalation to 140\u00a0mg. The same applies to the secondary endpoints and covers the entire study population as well as the subgroups of chronic and episodic migraine. The 50% response of the 70\u00a0mg non-responders for escalation was only 5.14%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this difficult-to-treat patient cohort we reconfirmed the effectiveness of erenumab, but could not detect any additional benefit for a dosage escalation from 70\u00a0mg to 140\u00a0mg erenumab.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s13760-024-02603-z","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T06:02:45Z","timestamp":1722060165000},"page":"1663-1670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Erenumab escalation in migraine - double dose without additional benefit - a retrospective experience"],"prefix":"10.1007","volume":"124","author":[{"given":"Simon","family":"Heintz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Storch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Burow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Maier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Obermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grit","family":"Stoessel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Kraya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1727-9362","authenticated-orcid":false,"given":"Steffen","family":"Naegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,27]]},"reference":[{"key":"2603_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1474-4422(19)30411-9","volume":"19","author":"VL Feigin","year":"2020","unstructured":"Feigin VL, Vos T, Nichols E et al (2020) The global burden of neurological disorders: translating evidence into policy. Lancet Neurol 19:255\u2013265. https:\/\/doi.org\/10.1016\/S1474-4422(19)30411-9","journal-title":"Lancet Neurol"},{"key":"2603_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1177\/0333102421989601","volume":"41","author":"K Drellia","year":"2021","unstructured":"Drellia K, Kokoti L, Deligianni CI et al (2021) Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. Cephalalgia 41:851\u2013864. https:\/\/doi.org\/10.1177\/0333102421989601","journal-title":"Cephalalgia"},{"key":"2603_CR3","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y et al (2017) A controlled trial of Erenumab for episodic migraine. N Engl J Med 377:2123\u20132132. https:\/\/doi.org\/10.1056\/NEJMoa1705848","journal-title":"N Engl J Med"},{"key":"2603_CR4","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392:2280\u20132287. https:\/\/doi.org\/10.1016\/S0140-6736(18)32534-0","journal-title":"Lancet"},{"key":"2603_CR5","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U et al (2021) Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28:1716\u20131725. https:\/\/doi.org\/10.1111\/ene.14715","journal-title":"Eur J Neurol"},{"key":"2603_CR6","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1177\/0333102418788347","volume":"38","author":"M Ashina","year":"2018","unstructured":"Ashina M, Tepper S, Brandes JL et al (2018) Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 38:1611\u20131621. https:\/\/doi.org\/10.1177\/0333102418788347","journal-title":"Cephalalgia"},{"key":"2603_CR7","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL et al (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38:1026\u20131037. https:\/\/doi.org\/10.1177\/0333102418759786","journal-title":"Cephalalgia"},{"key":"2603_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:425\u2013434. https:\/\/doi.org\/10.1016\/S1474-4422(17)30083-2","journal-title":"Lancet Neurol"},{"key":"2603_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s42466-020-00057-1","volume":"2","author":"H-C Diener","year":"2020","unstructured":"Diener H-C, F\u00f6rderreuther S, Gaul C et al (2020) Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: addition to the S1 guideline: therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German migraine and Headache Society. Neurol Res Pract 2:11. https:\/\/doi.org\/10.1186\/s42466-020-00057-1","journal-title":"Neurol Res Pract"},{"key":"2603_CR10","doi-asserted-by":"publisher","unstructured":"(2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"2603_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","volume":"21","author":"A Scheffler","year":"2020","unstructured":"Scheffler A, Messel O, Wurthmann S et al (2020) Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 21:84. https:\/\/doi.org\/10.1186\/s10194-020-01151-0","journal-title":"J Headache Pain"},{"key":"2603_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21:61. https:\/\/doi.org\/10.1186\/s10194-020-01127-0","journal-title":"J Headache Pain"},{"key":"2603_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s10194-020-01214-2","volume":"22","author":"J Talbot","year":"2021","unstructured":"Talbot J, Stuckey R, Crawford L et al (2021) Improvements in pain, medication use and quality of life in onabotulinumtoxina-resistant chronic migraine patients following erenumab treatment - real world outcomes. J Headache Pain 22:5. https:\/\/doi.org\/10.1186\/s10194-020-01214-2","journal-title":"J Headache Pain"},{"key":"2603_CR14","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1111\/head.13968","volume":"60","author":"S Cheng","year":"2020","unstructured":"Cheng S, Jenkins B, Limberg N, Hutton E (2020) Erenumab in Chronic Migraine: an Australian experience. Headache 60:2555\u20132562. https:\/\/doi.org\/10.1111\/head.13968","journal-title":"Headache"},{"key":"2603_CR15","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/head.13951","volume":"60","author":"J Robblee","year":"2020","unstructured":"Robblee J, Devick KL, Mendez N et al (2020) Real-world patient experience with erenumab for the preventive treatment of migraine. Headache 60:2014\u20132025. https:\/\/doi.org\/10.1111\/head.13951","journal-title":"Headache"},{"key":"2603_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/0333102420912726","volume":"40","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, Ashina M, Reuter U et al (2020) Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia 40:543\u2013553. https:\/\/doi.org\/10.1177\/0333102420912726","journal-title":"Cephalalgia"},{"issue":"1","key":"2603_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/head.14218","volume":"62","author":"J Gladstone","year":"2022","unstructured":"Gladstone J, Chhibber S, Minhas J (2022) Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: retrospective real\u2010world study. Headache: J Head Face Pain 62(1):78\u201388. https:\/\/doi.org\/10.1111\/head.14218","journal-title":"Headache: J Head Face Pain"},{"key":"2603_CR18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.2174\/1570159X19666210823104916","volume":"20","author":"Y Yang","year":"2022","unstructured":"Yang Y, Chen M, Wu D et al (2022) Optimal dose of Erenumab for Preventive Treatment of episodic migraine: a systematic review and Meta-analysis. Curr Neuropharmacol 20:460\u2013470. https:\/\/doi.org\/10.2174\/1570159X19666210823104916","journal-title":"Curr Neuropharmacol"},{"key":"2603_CR19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/03331024211048765","volume":"42","author":"LH Overeem","year":"2022","unstructured":"Overeem LH, Peikert A, Hofacker MD et al (2022) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia 42:291\u2013301. https:\/\/doi.org\/10.1177\/03331024211048765","journal-title":"Cephalalgia"},{"key":"2603_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11916-009-0048-3","volume":"13","author":"ME Bigal","year":"2009","unstructured":"Bigal ME, Lipton RB (2009) Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep 13:301\u2013307. https:\/\/doi.org\/10.1007\/s11916-009-0048-3","journal-title":"Curr Pain Headache Rep"},{"key":"2603_CR21","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1212\/01.wnl.0000335946.53860.1d","volume":"71","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Lipton RB (2008) Excessive acute migraine medication use and migraine progression. Neurology 71:1821\u20131828. https:\/\/doi.org\/10.1212\/01.wnl.0000335946.53860.1d","journal-title":"Neurology"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02603-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-024-02603-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02603-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T11:05:17Z","timestamp":1733223917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-024-02603-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,27]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2603"],"URL":"https:\/\/doi.org\/10.1007\/s13760-024-02603-z","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"type":"print","value":"0300-9009"},{"type":"electronic","value":"2240-2993"}],"subject":[],"published":{"date-parts":[[2024,7,27]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PS, PB, TK and SN received lecture fees from Novartis. PS and SN were also provided with a research grant from Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}